Identification of a novel orally bioavailable ERK5 inhibitor with selectivity over p38α and BRD4
Year: 2019
Type: article
Authors: Stephanie M. Myers, Duncan C. Miller, Lauren Molyneux, Mercedes Arasta, Ruth H. Bawn, Timothy J. Blackburn, Simon J. Cook, Noel Edwards, Jane A. Endicott, Bernard T. Golding, Roger J. Griffin, Tim Hammonds, Ian R. Hardcastle, Suzannah J. Harnor, Amy B. Heptinstall, Pamela A. Lochhead, Mathew P. Martin, Nick C. Martin, David R. Newell, Paul J. Owen, Leon C. Pang, Tristan Reuillon, Laurent J.M. Rigoreau, Huw D. Thomas, Julie A. Tucker, Lan-Zhen Wang, Ai-Ching Wong, Martin E.M. Noble, Stephen R. Wedge, Celine Cano
Institutions: Newcastle University, Babraham Institute, Cancer Research UK
Language: English
Topic: Melanoma and MAPK Pathways
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: closed
Awards: Signalling mechanisms that determine the rate of ageing, G2284497706, G5731676966, Discovery of ERK5 inhibitors for biomarker-driven clinical evaluation in cancer, G6580186668, Defining the role of ERK5 kinase and ERK5 transcriptional activities in cell migration and EMT using novel ERK5 inhibitors, G8564538711, G8735510888
OpenAlex ID: W2945809886